Brief: Initiator Pharma To Fully Prioritize Pudafensine

Initiator Pharma A/S

17/04/2026 08:09

April 17 (Reuters) - Initiator Pharma A/S INIT.ST:

INITIATOR PHARMA TO FULLY PRIORITIZE PUDAFENSINE

TO FOCUS FULLY ON ITS MOST PROMISING DRUG CANDIDATE, PUDAFENSINE

WILL DISCONTINUE FURTHER DEVELOPMENT OF IP2018

RESOURCES FROM IP2018 TO BE REDIRECTED TO PUDAFENSINE DEVELOPMENT

PUDAFENSINE PHASE IIA STUDY IN VULVODYNIA EXPECTED TO COMPLETE BY END 2026

ADDITIONAL PROOF-OF-CONCEPT DATA IN VULVODYNIA EXPECTED BEFORE YEAR-END

Source text: ID:nMFN4Gkc55

Further company coverage: INIT.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))